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Aim To validate and cross-culturally adapt Croatian and 
Serbian versions of composite autonomic symptom score-
31 (COMPASS-31) for the detection of dysautonomia in pa-
tients with multiple sclerosis (MS).
Methods A total of 179 patients, 67 with clinically isolated 
syndrome (CIS) and 112 with MS, completed the COMPASS-
31 at two MS centers in Zagreb and Belgrade between April 
1 and October 31, 2016. Demographic and clinical data in-
cluding age, gender, MS phenotypes, and the Expanded 
Disability Status Scale (EDSS) score were collected.
Results The Cronbach’s alpha coefficient of COMPASS-31 
total score was 0.844 for the Croatian MS sample and 0.779 
for the Serbian MS sample. A joint analysis yielded Cron-
bach’s alpha coefficients ranging from 0.394 to 0.796, with 
values in four domains higher than 0.700. In Croatian and 
Serbian samples and the total study sample, the Cronbach’s 
alpha coefficient of COMPASS-31 was 0.785. Reproducibil-
ity measured by intra-class correlation coefficient (ICC) was 
acceptable (ICC = 0.795). With regard to the clinical valid-
ity, significant correlation was found between EDSS and 
the COMPASS-31 total score (P < 0.001). Furthermore, sig-
nificant differences between MS phenotypes were detect-
ed for bladder and gastrointestinal domains and for the 
COMPASS-31 total score (P < 0.001, P = 0.005, and P = 0.027, 
respectively). Finally, significant differences between MS 
phenotypes in patients with score >0, which implies the 
existence of at least one of the symptoms investigated in 
each domain, were detected for secretomotor and bladder 
domains (P = 0.015 and P < 0.001, respectively).
Conclusion COMPASS-31 represents a valid and accept-
able self-assessment instrument for the detection of dys-
autonomia in MS patients.
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In recent years, a high percentage of autonomic nervous 
system (ANS) involvement in neurological diseases such as 
multiple sclerosis (MS) has been reported (1). ANS research 
usually consists of the investigation of patient-reported 
symptoms using different questionnaires and assessment of 
the ANS function in the laboratory. The latter shows limited 
reproducibility because the data are obtained with numer-
ous autonomic function tests, which are indirect, relatively 
imprecise, and fraught with difficulties. A recently published 
meta-analysis showed that the proportion of MS patients 
diagnosed with cardiovascular dysautonomia varies largely 
depending on the number of tests used (2). The best way to 
overcome this problem is to use a standardized battery of val-
idated and reproducible tests that can be interpreted in the 
form of a score. This enables detection, staging, and follow-
up of dysautonomia in different neurological and non-neu-
rological disorders. The Composite Autonomic Scoring Scale 
(CASS) is such a test. It has been successfully used in patients 
with multiple system atrophy, Parkinson disease, and auto-
nomic neuropathy (3). So far, CASS has only been evaluated 
in patients with clinically isolated syndrome (CIS) suggestive 
of MS in whom it can detect dysautonomia, which is restrict-
ed to sympathetic nervous system involvement (4).
All above-mentioned problems are even more emphasized 
when symptoms of ANS dysfunction are investigated. Even 
patients with severe sympathetic dysfunction, defined as 
orthostatic hypotension with a decrease in systolic blood 
pressure greater than 60 mm Hg from baseline during a 
head-up tilt table test, can be completely asymptomatic 
during the head-up tilt table test in up to one-third of the 
cases (5). Furthermore, in conditions such as fibromyalgia, 
a significant discrepancy between ANS symptoms and ob-
jective assessments of ANS dysfunction have been found 
(6). Therefore, a composite autonomic symptom score-31 
(COMPASS-31) was developed and found to be suitable for 
a widespread use in research and practice (7). COMPASS-
31 consists of 31 items quantifying 6 autonomic domains 
as follows: orthostatic intolerance, vasomotor, secretomo-
tor, gastrointestinal, bladder, and pupillomotor. Although 
there have been no standardized questionnaires on auto-
nomic dysfunction specifically validated for use in MS pa-
tients, COMPASS-31 has been used recently for the evalu-
ation of autonomic dysfunction in MS and confirmed that 
it can detect ANS dysfunction in MS. This finding implied 
that autonomic symptoms are present early in the disease 
and in patients with low disability (8).
The aim of the present study was to validate and cross-cul-
turally adapt Croatian and Serbian versions of COMPASS-
31 for the detection of dysautonomia in patients with MS. 
Additionally, we examined whether COMPASS-31 and its 
domains produce scores that differ across various MS phe-
notypes, including CIS.
PATIENTS AND METHODS
Patients
A total of 179 subjects, 67 patients with CIS and 112 with MS 
who received regular follow-up care at the Clinic of Neurol-
ogy, Clinical Center of Serbia, Belgrade, Serbia and Depart-
ment of Neurology, University Hospital Center Zagreb, Croa-
tia, between April 1, 2016 and October 31, 2016 were asked 
to complete the COMPASS-31 questionnaire. The diagnosis 
of CIS was made if a patient had acute or subacute develop-
ment of neurological symptoms and/or signs lasting longer 
than 48 hours in the absence of fever or infection, and with 
at least one demyelinating lesion larger than 3 mm on the 
brain and/or spinal cord MRI (9). The diagnosis of MS was 
made according to the Revised McDonald Criteria 2010 (10). 
The majority of MS patients from Zagreb, Croatia, belonged 
to the cohort of patients with CIS in whom special attention 
was paid to the investigation of ANS dysfunction in the Re-
ferral Center for Autonomic Nervous System Disorders.
Data on age, gender, clinical course, and the Expanded Dis-
ability Status Scale (EDSS) score (11) were collected by neu-
rologists after the physical examination of each patient.
COMPASS-31
The COMPASS-31 was translated from English to Serbian 
and from English to Croatian (12). All translated question-
naire items were first discussed by two independent trans-
lators for both languages and then back-translated to Eng-
lish by bilingual translators who were blinded to the original 
questionnaire. Subsequently, translators, MS specialists, and 
researchers discussed controversial items to generate the 
versions of the COMPASS-31 that would be the most ap-
propriate for the cultural environments in Serbia and Croa-
tia for testing MS patients. To check the understanding and 
interpretation of the translated items by Serbian and Croa-
tian populations, the Serbian and Croatian versions of the 
questionnaire were tested on five MS patients in each cen-
ter. The results of these tests were discussed by the same 
groups of specialists. Patients’ suggestions regarding the 
questionnaire were also taken into consideration. This 
stage led to the final, culturally adapted Serbian and 
Croatian versions of the COMPASS-31.
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The COMPASS-31 was scored according to the original rec-
ommendations (7). The total score ranges from 0 to 100, 
with higher values representing more severe symptoms. 
After expert revisions of the original version, questions and 
domains were further reduced and a total of 31 questions 
in 6 domains remained. In our study, the COMPASS-31 was 
completed by MS patients in the presence of a physician 
who could provide assistance, if needed.
To assess reproducibility, the same two groups of patients 
with MS completed the COMPASS-31 again after two 
weeks.
Statistical analysis
Descriptive statistical analysis of all variables was per-
formed. Normality of distribution was assessed by Kolmog-
orov-Smirnov test. For comparison of normally distributed 
variables, Student’s t-test was used, while χ2 test was per-
formed for comparison of categorical variables. In case of 
non-normal distribution, Mann-Whitney U test was used.
Internal consistency of the Serbian and Croatian versions 
of the COMPASS-31 was evaluated using Cronbach’s alpha 
coefficient (13), which ranged from 0 to 1. Test-retest reli-
ability of scores was evaluated by calculation of the test/
retest correlation (intra-class correlation coefficient, ICC).
Clinical validity was assessed by correlating the mean 
COMPASS-31 total and domain scores with EDSS score. 
Spearman’s correlation coefficient was used to determine 
the relationship between the COMPASS-31 scores and the 
EDSS score. Differences between groups were assessed by 
ANOVA and post hoc Tukey’s test for parametric variables, 
and by Kruskal-Wallis and Mann-Whitney U test for non-
parametric variables.
Receiver operating characteristic (ROC) curve analysis was 
used to determine the cut-off value of COMPASS-31 total 
score for the identification of MS patients with and those 
without the investigated symptoms. In this ROC analysis, 
the COMPASS-31 total and domain scores were depen-
dent variables and the status of MS patient (presence or 
absence of autonomic dysfunction) was the independent 
variable. Separate ROC analyses were performed for each 
domain of the COMPASS-31.
Significance level was set at P < 0.05. Data analysis was per-
formed using SPSS 17.0 (SPSS Inc., Chicago, IL, USA).
RESULTS
Translation and validation of the questionnaire
All 179 patients were able to read and comprehend the 
questionnaire. Most found the questionnaire acceptable, 
clear, and understandable. None of the items were found 
to be disagreeable. Median time to complete the ques-
tionnaire was 8 minutes (range, 4-31 minutes). Twenty-one 
(11.7%) patients needed help, 11 (6.1%) patients required 
help with reading because of lower visual acuity, and 10 
(5.6%) patients required writing assistance.
Based on the differences in the frequency of MS pheno-
types, there was a difference in all patient characteristics 
except for gender (Table 1).
TAbLE 1. Demographic and clinical characteristics of patients with multiple sclerosis (MS) in Serbia and Croatia*
No. (%) of MS patients
Variable Serbia (n = 102) Croatia (n = 77) total (N = 179)
Gender
men 35 (34.3) 29 (37.7)  64 (35.8)
women 67 (65.7) 48 (62.3) 115 (64.2)
Age (years; mean±SD) 42.2 ± 12.8 33.3 ± 9.4  38.4 ± 12.3
range 19-75 19-57  19-75
EDSS (score; mean±SD)  3.8 ± 2.7  1.9 ± 1.4   2.8 ± 2.1
range  0.0-8.0  0.0-6.5   (0.0-8.0)
MS phenotype
CIS 11 (10.8) 56 (72.7)  67 (37.4)
RRMS 58 (56.9) 19 (24.7)  77 (43.0)
SPMS 20 (19.6)  1 (1.3)  21 (11.7)
PPMS 13 (12.7)  1 (1.3)  14 (7.8)
*Abbreviations: SD – standard deviation, EDSS – Expanded Disability Status Scale, CIS – clinically isolated syndrome, RRMS – relapsing remitting 
multiple sclerosis, SPMS – secondary progressive multiple sclerosis, PPMS – primary progressive multiple sclerosis.
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The Cronbach’s alpha coefficient of COMPASS-31 domains 
in Serbian MS sample ranged from 0.409 to 0.820, with 
three domains reaching a value above 0.700 (Table 2). In 
the Croatian MS sample, Cronbach’s alpha coefficient of 
COMPASS-31 domains ranged from 0.412 to 0.851, with 
four domains reaching a value above 0.700. In the joint 
analysis, Cronbach’s alpha coefficients ranged from 0.394 
to 0.796, with values in four domains being higher than 
0.700. Finally, in both Serbian and Croatian sample and the 
total group the Cronbach’s alpha coefficient of COMPASS-
31 was higher than 0.700. Reproducibility measured by ICC 
was acceptable (ICC = 0.795).
Clinical validity
Statistically significant correlation (P < 0.001) was found 
between EDSS score and the COMPASS-31 total score 
(Table 3). Additionally, scores in gastrointestinal and blad-
der domains showed a strong correlation with the EDSS 
(ρ = 0.333; P < 0.001 for gastrointestinal domain, and 
ρ = 0.563; P < 0.001 for bladder domain). One other factor 
significantly related to the EDSS was secretomotor domain 
(ρ = 0.179; P = 0.019). Orthostatic intolerance, vasomotor 
and pupillomotor domains were not related to the EDSS.
The mean COMPASS-31 domain scores in four different MS 
phenotypes (CIS, relapsing-remitting MS, secondary pro-
gressive MS, and primary progressive MS) showed signifi-
TAbLE 2. Descriptive characteristics and internal reliability of 
composite autonomic symptom score-31 (COMPASS-31) in 
Serbian and Croatian patients with multiple sclerosis (MS)
COMPASS-31 domains
median 
(interquartile range) Cronbach α
Serbian MS patients
orthostatic intolerance  0 (0) 0.641
vasomotor  0 (0) 0.409
secretomotor  0 (4.3) 0.662
gastrointestinal  4.5 (6.5) 0.798
bladder  1.7 (3.3) 0.705
pupillomotor  1.0 (1.7) 0.820
total score 13.9 (20.0) 0.779
Croatian MS patients
orthostatic intolerance  0 (12.0) 0.541
vasomotor  0 (0.8) 0.412
secretomotor  0 (2.1) 0.826
gastrointestinal  2.7 (5.4) 0.778
bladder  0 (1.7) 0.851
pupillomotor  1.0 (1.0) 0.730
total score  9.5 (18.0) 0.844
Total MS patients
orthostatic intolerance  0 (12.0) 0.610
vasomotor  0 (0.8) 0.394
secretomotor  0 (4.3) 0.725
gastrointestinal  3.5 (6.2) 0.785
bladder  0 (3.3) 0.764
pupillomotor  1.0 (1.7) 0.796
total score 12.2 (19.4) 0.785
TAbLE 3. Clinical validity of composite autonomic symptom 
score-31 (COMPASS-31) in Serbian and Croatian patients with 
multiple sclerosis (MS)
Expanded Disability Status Scale
COMPASS-31 domains Correlation coefficient (ρ) P
orthostatic intolerance 0.079 0.303
vasomotor 0.073 0.341
secretomotor 0.179 0.019
gastrointestinal 0.333 <0.001
bladder 0.563 <0.001
pupillomotor 0.095 0.214
Total score 0.266 <0.001
FIGURE 1. The ROC curve indicating effectiveness of compos-
ite autonomic symptom score-31 (COMPASS-31) total score 
in detection of patients with multiple sclerosis (MS) with the 
orthostatic intolerance domain score greater than 0. Orthos-
tatic intolerance domain. The area under the curve was 0.950. 
The optimal cut-off value for COMPASS-31 total score was 13.6, 
sensitivity was 0.944, and specificity was 0.824. The mean cut-
off value for COMPASS-31 total score was 16.3, sensitivity was 
0.845, and specificity was 0.898.
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cant differences between MS phenotypes in bladder and 
gastrointestinal domains and total score (Table 4). Statis-
tically significant differences in the proportion of partici-
pants with score >0, which implied the presence of at least 
one of the symptoms investigated in each domain, be-
tween MS phenotypes were detected in secretomotor and 
bladder domains (Table 5).
The ROC analysis was performed for each domain of the 
total sample (Figure 1). The highest sensitivity and speci-
ficity was detected for the orthostatic intolerance domain. 
According to the ROC curve for the orthostatic intolerance 
domain, 95% of the total area was under curve (Figure 1A). 
To differentiate between patients with the orthostatic in-
tolerance score greater than 0 and those with score 0, ie, 
those with and without autonomic dysfunction, respec-
tively, the optimal cut-off value for the orthostatic intol-
erance domain score was 13.6. The Serbian and Croatian 
versions of COMPASS-31 for MS patients who were expe-
riencing orthostatic intolerance symptoms before testing, 
the sensitivity was 94.4% and the specificity was 82.4% 
(Figure 1A). The ROC curves for the remaining domains are 
provided as supplementary material (Supplementary Ma-
terial).
DISCUSSION
The results of our study showed that Croatian and Serbian 
versions of COMPASS-31 were valid tools for quantitative 
assessment of the ANS in MS patients. Furthermore, COM-
PASS-31 together with some of its domains significantly 
correlated with the overall disability of MS patients as mea-
sured by EDSS. As COMPASS-31 was successfully used in 
the assessment of various neurological disorders (14,15), 
our study further expanded its use for the detection of dys-
autonomia in persons with MS.
We computed the scale reliability, presuming that ade-
quate reliability coefficients in our populations indicated 
that the scales measured by the COMPASS-31 were appro-
TAbLE 4. Descriptive characteristics of composite autonomic symptom score-31 (COMPASS-31) domains according to the multiple 
sclerosis (MS) phenotype*
MS phenotype (mean±SD)
COMPASS-31 domains CIS (n = 67) RRMS (n = 77) SPMS (n = 21) PPMS (n = 14) F P
orthostatic intolerance  5.9 ± 8.0  6.4 ± 8.8  7.4 ± 12.7  8.2 ± 10.5  0.340 0.796
vasomotor  0.3 ± 0.7  0.4 ± 0.8  0.3 ± 0.8  0.6 ± 2.7  0.744 0.527
secretomotor  1.4 ± 2.7  2.2 ± 3.3  2.1 ± 3.0  3.5 ± 2.9  2.143 0.097
gastrointestinal  3.5 ± 3.0  4.4 ± 4.2  6.1 ± 3.9†  6.7 ± 3.8†  4.499 0.005
bladder  0.8 ± 1.7  1.5 ± 2.0  3.1 ± 2.1†‡  4.9 ± 3.3†‡ 18.890 <0.001
pupillomotor  1.3 ± 1.0  1.3 ± 0.9  1.5 ± 0.9  1.0 ± 0.9  0.463 0.708
Total score 13.2 ± 12.9 16.3 ± 15.6 20.5 ± 18.9 25.2 ± 14.6†  3.133 0.027
*Abbreviations: SD – standard deviation, CIS – clinically isolated syndrome, RRMS – relapsing remitting multiple sclerosis, SPMS – secondary progres-
sive multiple sclerosis, PPMS – primary progressive multiple sclerosis.
†Tukey’s post hoc test, P < 0.01, in comparison with CIS.
‡Tukey’s post hoc test, P < 0.01 in comparison with relapsing remitting MS.
TAbLE 5. Proportion of patients with multiple sclerosis (MS) with a score >0 in each domain of the composite autonomic symptom 
score-31 (COMPASS-31) according to the MS phenotype
No. (%) of patients with MS phenotype
COMPASS-31 domains CIS RRMS SPMS PPMS P†
Orthostatic intolerance 28 (41.8) 31 (40.3)  6 (28.6)  6 (42.9) 0.736
Vasomotor 16 (28.6) 20 (26.0)  4 (19.0)  7 (50.0) 0.186
Secretomotor 18 (26.9) 31 (40.3)  9 (42.9) 10 (71.4)‡ 0.015
Gastrointestinal 56 (83.6) 63 (81.8) 20 (95.2) 12 (85.7) 0.513
Bladder 19 (28.4) 36 (46.8) 18 (85.7)‡ 12 (85.7)‡ <0.001
Pupillomotor 54 (80.6) 66 (85.7) 13 (61.9)  9 (64.3) 0.051
*Abbreviations: CIS – clinically isolated syndrome, RRMS – relapsing remitting multiple sclerosis, SPMS – secondary progressive multiple sclerosis, 
PPMS – primary progressive multiple sclerosis.
†Independent-samples Kruskal-Wallis test.
‡Mann-Whitney test, P < 0.01, in comparison with CIS.
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priately assessed. We found acceptable internal consisten-
cy and reliability of the translated versions of the question-
naire. Sletten et al (7) previously demonstrated Cronbach’s 
alpha coefficient of 0.700 and more for the original US Eng-
lish version and considered it acceptable.
Our results reconfirmed the psychometric characteristics 
of the questionnaire observed in other validation studies 
(14-16). Due to our study, COMPASS-31 became the first 
cross-culturally adapted self-assessment tool to evaluate 
dysautonomia in MS patients in Serbia and Croatia. To the 
best of our knowledge, so far only Italian version of the 
COMPASS-31 has been validated outside English speaking 
countries (15).
Clinical validity of COMPASS-31 was assessed by compar-
ing mean values of the domain and total scores with the 
EDSS score. We found that the EDSS score correlated sig-
nificantly positively with secretomotor, gastrointestinal, 
and bladder domains and total COMPASS-31 score. In a 
recently published study, the correlation between EDSS 
and COMPASS-31 was not found (8). However, only 41 pa-
tients completed the questionnaire, which could have in-
fluenced the findings (8). The other possible explanation 
is that parasympathetic and sympathetic components of 
the ANS are selectively impaired in different stages of MS 
(17). While sympathetic cardiovascular dysfunction is asso-
ciated with clinical activity of the disease, parasympathetic 
cardiovascular dysfunction generally correlates better with 
the level of clinical disability as measured by EDSS and dis-
ease duration (4,18). In our study, these differences were 
reflected in the total COMPASS-31 score and its domains 
among different MS phenotypes. Patients with progres-
sive forms of MS had significantly higher gastrointestinal 
and bladder domain scores and total COMPASS-31 score 
as compared with patients with CIS. It has already been re-
ported that bladder and gastrointestinal dysfunctions cor-
relate with higher levels of physical disability and occur 
more frequently in progressive forms of MS (19,20).
The ROC analysis was used to differentiate between the 
patients who do and those who do not experience symp-
toms of orthostatic intolerance. As our study was focused 
on cardiovascular ANS involvement in MS, a special em-
phasis was placed on orthostatic intolerance rather than 
other COMPASS-31 domains.
The cut-off score establishing the level of distinction be-
tween patients who do and those who do not experience 
symptoms of orthostatic intolerance was 13.6. The scale 
sensitivity was considerably high, indicating the capacity 
of the scale to identify patients with orthostatic intoler-
ance. Similar relationships were observed for the remain-
ing COMPASS-31 domains.
The main limitation of our study was that no laboratory 
testing of the ANS was performed to obtain objective neu-
rophysiological evidence of dysautonomia in MS patients. 
However, we hope that our ongoing project will shed more 
light on possible discrepancy between subjective and ob-
jective ANS dysfunction.
In conclusion, the availability of reliable testing methods 
remains critical in ANS research. The current validation is 
part of a large, collaborative, international study on dys-
autonomia in MS. The present study showed that COM-
PASS-31 is a valid and acceptable self-assessment instru-
ment for the detection of dysautonomia in MS patients, 
which may be useful to clinicians and researchers in Ser-
bia and Croatia for detection of this often overlooked clini-
cal problem in MS.
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